REG - AstraZeneca PLC - Grünenthal Agreement for Nexium, Vimovo Completed

AstraZenecaAnnouncement

03/12/2018 07:05

RNS Number : 1354J
AstraZeneca PLC
03 December 2018
 


3 December 2018 07:00 GMT
 
Agreement with Grünenthal for rights to Nexium in

Europe and Vimovo worldwide (ex-US) completed
 
AstraZeneca has completed an agreement to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal.
 
Under the terms of the agreement, AstraZeneca has received payments of $700m for Nexium and $115m for Vimovo from Grünenthal. The upfront payments, net of an appropriate derecognition of an intangible asset related to Vimovo (see below) will be reported within Other Operating Income & Expense in the Company's financial statements in the fourth quarter of 2018.
 
AstraZeneca will continue to commercialise Nexium in all markets outside Europe, where the Company retains the rights. AstraZeneca will not retain any ownership rights to Vimovo globally.
 
Pursuant to Listing Rule 10.4.1R (notification of class 2 transactions), the book value of gross assets subject to the divestments was approximately $99 million at 31 December 2017. In the year to 31 December 2017 the aggregate pre-tax profits attributable to Nexium and Vimovo in the relevant territories were $203 million. The consideration will be satisfied in cash and the proceeds used for general corporate purposes.
 
About Nexium
Nexium (esomeprazole) is used to treat gastroesophageal reflux disease, ulcers, and Zollinger-Ellison syndrome. It is also used for the prevention and treatment of gastric ulcers induced by pain-relieving NSAIDs. Nexium is available in several formulations (Nexium gastro-resistant granules for oral suspension, Nexium gastro-resistant Multi-Unit Pellet System (Nexium MUPS) tablets, and Nexium injection/infusion) with varying approved indications. The rights to over-the-counter Nexium were externalised to Pfizer Consumer Health in 2012.
 
About Vimovo
Vimovo (naproxen/esomeprazole) modified-release tablet is a fixed-dose combination of naproxen, a pain-relieving NSAID and esomeprazole, the active ingredient in Nexium. It is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing NSAID-associated gastric ulcers and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient. The rights to Vimovo in the United States were externalised to Horizon Pharma in 2013.
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 




Media Relations


 


 




Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jennifer Hursit


UK/Global


+44 203 749 5762




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677




 


 


 




Investor Relations




Thomas Kudsk Larsen


 


+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


Cardiovascular; Metabolism


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Josie Afolabi


Other


+44 203 749 5631




Craig Marks


Finance; Fixed Income


+44 7881 615 764




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free


 


+1 866 381 7277



 
 
 
 
 



 
Adrian Kemp

Company Secretary
AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRLLFLTLSLIVIT